指南与共识神经免疫

实践指南更新摘要:多发性硬化中的疫苗可预防感染与免疫接种

Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
指南 / 共识 · Neurology · 2019-08-28

美国神经病学学会(AAN)更新2002年指南,系统评价免疫接种与多发性硬化(MS)的证据。推荐MS患者按本地疫苗标准接种、每年接种流感疫苗,使用免疫抑制/免疫调节(ISIM)药物前筛查感染并避免减毒活疫苗,复发期延迟接种。

要点

  • MS患者应遵循本地疫苗标准,每年接种流感疫苗。
  • 使用ISIM药物前需筛查感染,至少提前4-6周接种所需疫苗。
  • 接受ISIM治疗者禁用减毒活疫苗,复发期应延迟接种。

核心结论

  • MS患者应遵循本地疫苗标准并每年接种流感疫苗,使用ISIM药物前后需按说明书筛查感染和接种疫苗,禁用减毒活疫苗。

研究设计与样本

  • 指南制定小组进行系统评价,采用AAN分类系统对文献分级,推荐基于证据、相关证据、照护原则和推论。

主要发现

  • 推荐MS患者每年接种流感疫苗(Level B)。
  • 使用ISIM药物前至少4-6周接种所需疫苗(Level B)。
  • 启动ISIM药物前必须按说明书筛查感染(Level A),并治疗潜伏感染阳性者。
  • 高危人群启动ISIM前必须筛查潜伏感染(Level A),阳性者应咨询专家治疗。
  • 接受ISIM治疗的MS患者禁用减毒活疫苗(Level B),复发期应延迟接种(Level B)。

关键数值与推荐

  • 流感疫苗接种推荐为每年一次(Level B)。
  • 疫苗接种应在启动ISIM治疗前至少4-6周进行(Level B)。
  • 启动ISIM药物前筛查感染为Level A推荐。
  • 高危人群筛查潜伏感染为Level A推荐。
  • 减毒活疫苗禁用于接受ISIM治疗的MS患者(Level B)。

临床怎么用

  • 临床医生应与MS患者讨论免疫接种证据,并考虑患者意见和当地疫苗可预防疾病风险。
  • 使用ISIM药物前按说明书筛查感染,治疗潜伏感染,高危人群即使说明书未提及也应筛查。
  • 接受ISIM治疗者避免减毒活疫苗,复发期延迟接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To update the 2002 American Academy of Neurology (AAN) guideline regarding immunization and multiple sclerosis (MS). METHODS: The panel performed a systematic review and classified articles using the AAN system. Recommendations were based on evidence, related evidence, principles of care, and inferences according to the AAN 2011 process manual, as amended. MAJOR RECOMMENDATIONS LEVEL B EXCEPT WHERE INDICATED: Clinicians should discuss the evidence regarding immunizations in MS with their patients and explore patients' opinions, preferences, and questions. Clinicians should recommend that patients with MS follow all local vaccine standards, unless there are specific contraindications and weigh local vaccine-preventable disease risks when counseling patients. Clinicians should recommend that patients with MS receive the influenza vaccination annually. Clinicians should counsel patients with MS about infection risks associated with specific immunosuppressive/immunomodulating (ISIM) medications and treatment-specific vaccination guidance according to prescribing information (PI) and vaccinate patients with MS as needed at least 4-6 weeks before initiating patients' ISIM therapy. Clinicians must screen for infections according to PI before initiating ISIM medications (Level A) and should treat patients testing positive for latent infections. In high-risk populations, clinicians must screen for latent infections before starting ISIM therapy even when not specifically mentioned in PI (Level A) and should consult specialists regarding treating patients who screen positive for latent infection. Clinicians should recommend against using live-attenuated vaccines in people with MS receiving ISIM therapies. Clinicians should delay vaccinating people with MS who are experiencing a relapse.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019. PMID: 31462584. doi:10.1212/WNL.0000000000008157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。